Gene Expression Profiling and Non–Small-Cell Lung Cancer: Where Are We Now?
Clinical Lung Cancer, ISSN: 1525-7304, Vol: 10, Issue: 3, Page: 168-173
2009
- 18Citations
- 30Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations18
- Citation Indexes18
- 18
- CrossRef13
- Captures30
- Readers30
- 30
Review Description
Despite new developments in molecular techniques and better knowledge on lung cancer tumor biology, many genetic alterations associated with the development and progression of lung carcinogenesis still remain unclear. Although the development of targeted agents has improved response rates and survival, lung cancer has a very high mortality rate, even for early stages. Thus, there is a greater need for other mechanisms or technologies that may help us diagnose, predict, and treat patients with lung cancer in a more effective way. One of these technologies has been the use of genomics. Some of the available genomic technologies include single-nucleotide polymorphism analysis, high-throughput capillary sequencing, serial analysis of gene expression, and gene expression arrays. DNA microarray analysis is capable of discovering changes in DNA expression within the neoplastic tumor. Thus, gene expression array could help us to decipher the complexity and interaction of different oncogenic pathways and, hence, could contribute to the selection of better targeted agents on an individual basis rather than a general and nonspecific approach as it has been done for many decades. Several studies initiated a few years ago have started to produce fruitful results. Herein, we review the role of gene expression profiling in lung cancer as a diagnostic tool, predictive and prognostic biomarker, and its potential use for a “personalized” medicine in the years to come.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1525730411704806; http://dx.doi.org/10.3816/clc.2009.n.023; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=67649402150&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/19443336; http://linkinghub.elsevier.com/retrieve/pii/S1525730411704806; http://cigjournals.metapress.com/index/10.3816/CLC.2009.n.023; http://api.elsevier.com/content/article/PII:S1525730411704806?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S1525730411704806?httpAccept=text/plain; https://linkinghub.elsevier.com/retrieve/pii/S1525730411704806; https://dx.doi.org/10.3816/clc.2009.n.023
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know